# A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Source: https://onco.cc/trials/nct06430437/  
OnCo record `nct06430437` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab rezetecan, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations is a phase 3 interventional study registered as NCT06430437 by Jiangsu HengRui Medicine Co., Ltd., with 300 participants planned, started 2024-07-29 and due to reach its primary completion in 2026-02. Interventions recorded: SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin. Conditions listed: Non-Small Cell Lung Cancer With HER2- Mutations. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06430437
- Phase: 3
- Setting: A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06430437: https://clinicaltrials.gov/study/NCT06430437

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06430437.json